First-Line Treatments for Chemotherapy-Ineligible AML

In the phase 1b/2 FELIX study, obecabtagene autoleucel was associated with low incidence of grade 3 or higher immune-related toxicity.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.